Compare YMT & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | CLGN |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 18.4M |
| IPO Year | N/A | 2015 |
| Metric | YMT | CLGN |
|---|---|---|
| Price | $0.22 | $0.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 13.4M | 128.3K |
| Earning Date | 06-09-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $240.45 |
| Revenue Next Year | N/A | $38.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.27 |
| 52 Week High | $2.40 | $4.98 |
| Indicator | YMT | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 36.00 |
| Support Level | $0.15 | N/A |
| Resistance Level | $0.35 | $0.73 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 31.78 | 28.75 |
Yimutian Inc is the largest agricultural B2B platform in mainland China. It provide a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching, matching, to transaction facilitation and settlement. The company pride itself as the go-to platform for merchants by leveraging its inventive technology and industry know-how. Its platform had over 38 million merchants. It has also established approximately 12 offline stores in mainland China to trade agricultural products at cultivation and production sites with sellers and buyers.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.